Sat.Jul 26, 2025 - Fri.Aug 01, 2025

article thumbnail

Research progress on covalent inhibitors targeting alkaline amino acids

Covalent Modifiers

Bing Zhao, Sha Xu, Shiqing Zhou, Xiangru Jiang, Ailin Jiang, Hongrui Lei, Xin Zhai Bioorganic Chemistry, 163, 2025, 108800, [link] [link] the past two decades, covalent inhibitors have undergone a remarkable resurgence in drug discovery. Currently, targeting non-catalytic cysteine residues with acrylamide and other α,β-unsaturated carbonyl compounds is a predominate strategy, especially in the protein kinase field.

article thumbnail

A Visual Guide to Gene Delivery

Codon

A gene is the essential hereditary unit that passes traits from parents to offspring; a segment of DNA containing instructions for making a specific protein or molecule that performs a particular function in your body. And yet, despite being fundamental to our flourishing, genes can be broken. Researchers have identified nearly 10,000 monogenic diseases , or conditions caused by errors in a single gene.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ivermectin: The mosquito-killing pill that dropped malaria by 26%

Science Daily: Pharmacology News

A groundbreaking study has revealed that the mass administration of ivermectin—a drug once known for treating river blindness and scabies—can significantly reduce malaria transmission when used in conjunction with bed nets.

article thumbnail

Fixing failed drugs: AI solutions for toxicity in drug discovery – part 3

Drug Target Review

When discussing how newer AI technologies like large language models (LLMs) could contribute to toxicity prediction, Hosseini-Gerami identified two key applications: 1. Improved scientist–data interaction: “Once we have all these datasets, have run these algorithms and have some outcomes and outputs, how can a scientist really engage with that information and use it to make a decision on what to do next?

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

Off-target toxicity in antibody-drug conjugates

Crown Bioscience

Antibody-drug conjugates (ADCs) are among the most exciting advances in target cancer therapy. They combine the specificity of monoclonal antibodies with the cytotoxic potency of small molecule drugs to focus treatment on malignant cells while reducing damage to healthy cells.

article thumbnail

Repurposing of FDA‐Approved Drugs to Disrupt Iron Uptake in Mycobacterium abscessus: Targeting Salicylate Synthase as a Novel Approach

Chemical Biology and Drug Design

A drug repurposing strategy was applied against M. abscessus, through a virtual screening of FDA approved drugs on salicylate synthase. Eleven potential ligands were found; among these, three were confirmed as potent inhibitors of the enzyme. ABSTRACT Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that lead to severe, persistent infections, particularly in immunocompromised or vulnerable individuals.

More Trending

article thumbnail

Eight Key Considerations for Evaluating FSP Partners Offering Remote-Based Regional Hubs

PPD

Biopharma and biotech industries are facing remarkable challenges as the cost of developing new drugs has surged dramatically and clinical trial timelines have extended significantly. For example, over the past decade, the average time required to complete a clinical trial has increased by approximately 20-30%. These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 billion (versus $1-1.5 billion just a decade ago).

article thumbnail

Cracking the Code: Using Drug Patents to Reveal Competitor Formulation Strategies

Drug Patent Watch

Uncovering the Secret Formulas: How Drug Patents Reveal the Competition's Playbook As the pharmaceutical industry continues to evolve, companies are under increasing pressure to innovate and stay ahead of the curve. But what if the key to unlocking your competitors' strategies lies in plain sight – hidden in the complex web of drug patents? A new analysis from Drug Patent Watch reveals the surprising ways in which competitors are using patent data to inform their formulation strategies.

article thumbnail

Merck plans spending shift to boost business beyond Keytruda

BioPharma Drive: Drug Pricing

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support of newer drugs and R&D.

article thumbnail

Vault Snack #30 – Additional Curve Fits for Plotting and Analysing Assay Data in CDD Vault

Collaborative Drug

Skip to content Login Search { Products CDD Vault Why CDD Vault Core Functionality Registration Activity Visualization Assays Add-ons ELN Inventory Curves AI AI + Automation Solutions Applications Assay Data Management Macrocycle Protein Therapeutic CRISPR PROTAC Antibody Drug Conjugate Small Molecules & Mixtures Industries Biotech & Pharmaceutical CRO Academics Agritechnology Consortia & Collaborations Consumer Goods User Roles Research Scientist Operations/IT Legal/Regulatory Execu

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Harnessing TnpB for Genome Editing: A Compact and Versatile Tool for Your Research

addgene Blog

This blog post was written by Dr. Kutubuddin Molla, investigator at ICAR-Central National Rice Research Institute. When it comes to genome editing, CRISPR is a name that resonates with nearly every biologist, academic, and researcher. Among the most well-known CRISPR-associated nucleases are Cas9 and Cas12a, the heavyweights in the genome editing toolbox.

article thumbnail

Oyez, Oyez, Oyez! Effective August 1, DEA Will Have No Administrative Law Judges

FDA Law Blog: Biosimilars

By John A. Gilbert & Karla L. Palmer & Larry K. Houck & Andrew J. Hull — Last week, DEA registrants and applicants with pending actions before DEA’s Office of Administrative Law Judges (OALJ) received an order from Chief Administrative Law Judge John J. Mulrooney, II, staying the hearing proceedings in those cases. In those orders, Chief Judge Mulrooney announced that he was retiring from the bench effective August 1, 2025, and that, in the absence of any other DEA ALJs, all proceed

article thumbnail

GenAI and real-world data in pharma: 4 questions to fuel effective insights

BioPharma Drive: Drug Pricing

Skip to main content Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

article thumbnail

Why smarter financial planning could be key to clinical trial success

Drug Target Review

Effective financial management is a cornerstone in the success of clinical trials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer. Jennifer Kyle, Founder and CEO of Condor Software, has witnessed these challenges first-hand and developed a solution aimed at bridging the gap between financial management and clinical

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

PADER: A Key Pharmacovigilance Requirement for the U.S. Market

thought leadership

Pharmacovigilance is a global responsibility, and regulatory requirements may differ significantly depending on the region. One such region-specific requirement is the Periodic Adverse Drug Experience Report (PADER) , a post-marketing safety report mandated by the U.S. Food and Drug Administration (FDA). While many in the pharmaceutical industry may already be familiar with the Periodic Safety Update Report (PSUR) , which we previously covered on our website, understanding how PADER differs from

article thumbnail

How Science Can Drive Better Business Decisions in Biopharma

Fierce BioTech

How Science Can Drive Better Business Decisions in Biopharma A scientific approach to decision-making can improve clinical development, as well as corporate, portfolio, & product strategy. Here’s a framework. jpiatt Tue, 07/29/2025 - 09:28 A scientific approach to decision-making can improve clinical development, as well as corporate, portfolio, & product strategy.

article thumbnail

You’ve never seen atoms like this before: A hidden motion revealed

Science Daily: Pharmacology News

A pioneering team at the University of Maryland has captured the first-ever images of atomic thermal vibrations, unlocking an unseen world of motion within two-dimensional materials. Their innovative electron ptychography technique revealed elusive “moiré phasons,” a long-theorized phenomenon that governs heat, electronic behavior, and structural order at the atomic level.

article thumbnail

COVID Vaccines Saved More Than 2.5 Million Lives, Mostly Seniors

Drugs.com

MONDAY, July 28, 2025 — More than 2.5 million deaths were prevented worldwide by the cutting-edge vaccines developed for COVID-19, mainly among seniors, a new analysis says. Essentially, one death was averted for every 5,400 doses.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Business Continuity and Resiliency Planning for Biomedical and Research Organizations: A Strategic Imperative

Drug Patent Watch

Disruption in the Lab: Why Business Continuity Planning is a Lifeline for Biomedical Research As the life sciences industry grapples with unprecedented disruptions, from supply chain shortages to global pandemics, biomedical and research organizations are facing unprecedented challenges to their very existence. In our latest report, we explore the critical importance of business continuity and resiliency planning for these organizations, and why it's no longer a nicety, but a necessity.

article thumbnail

Novo cuts guidance, names new CEO as obesity drug challenges mount

BioPharma Drive: Drug Pricing

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its competition with rival Eli Lilly.

article thumbnail

Decades of chemistry rewritten: A textbook reaction just flipped

Science Daily: Pharmacology News

Penn State researchers have uncovered a surprising twist in a foundational chemical reaction known as oxidative addition. Typically believed to involve transition metals donating electrons to organic compounds, the team discovered an alternate path—one in which electrons instead move from the organic molecule to the metal. This reversal, demonstrated using platinum and palladium exposed to hydrogen gas, could mean chemists have misunderstood a fundamental step for decades.

article thumbnail

Personalized Brain Stimulation Improves Walking Among Parkinson's Patients

Drugs.com

MONDAY, July 28, 2025 — Parkinson’s disease can dramatically affect a patient’s ability to walk, with “Parkinson’s gait” increasing their fall risk and reducing their ability to get around. But deep brain.

article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

US and EU agree to trade deal with 15% tariff rate, questions remain on pharmaceuticals

Pharma Manufacturing

President Donald Trump and European Commission President Ursula von der Leyen appear to differ on how their trade agreement addresses pharma-specific tariffs.

article thumbnail

Cytotoxicity Assays – what your cells don’t like | BMG LABTECH

BMG Labtech

Advanced assay drug development technologies are increasingly used to evaluate cytotoxicity, enabling more efficient and accurate drug development. This article focuses on cytotoxicity assays. However, these are often combined with viability tests for normalization purposes.

article thumbnail

How to own a Market you Don’t Own: Market Access Strategies Post-Patent Expiration

Drug Patent Watch

"Unlocking the Secret to Market Supremacy: How to Own a Market You Don't Own As the pharmaceutical industry continues to evolve, one thing remains constant: the pursuit of market dominance. But what if you're not the first to market? What if your competitor has already established a stronghold on the market? In our latest report, we reveal the strategies that top pharmaceutical companies are using to gain market access and own a market they don't own.

article thumbnail

Autoantibodies Influence Cancer Response To Immunotherapy, Study Says

Drugs.com

MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoantibodies – immune proteins.

article thumbnail

An ‘impossible’ 20-electron molecule challenges 100 years of chemistry

Science Daily: Pharmacology News

Scientists at OIST have defied a foundational rule in chemistry by creating a stable 20-electron version of ferrocene—an organometallic molecule once thought to be limited to 18 valence electrons. This discovery not only challenges conventional wisdom but unlocks new chemical behaviors and redox states, potentially transforming how catalysts and materials are designed.

article thumbnail

Redefining commercial success in specialty lite with alternative channels

BioPharma Drive: Drug Pricing

Skip to main content Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy.

article thumbnail

Optimize Sitecore Docker Instance: Increase Memory Limits

Perficient: Drug Development

Running a Sitecore Docker instance is a game-changer for developers. It streamlines deployments, accelerates local setup, and ensures consistency across environments. However, performance can suffer – even on high-end laptops – if Docker resources aren’t properly optimized, especially after a hardware upgrade. I recently faced this exact issue.

article thumbnail

Is It Chronic Fatigue? Listen to Your Gut, Research Suggests

Drugs.com

TUESDAY, July 29, 2026 — Artificial intelligence (AI) may be guiding doctors towards a gut-focused means of accurately diagnosing chronic fatigue syndrome (CFS), new research shows.The illness appears to disrupt relationships between a person’s gut.

article thumbnail

Building electronics that don’t die: Columbia's breakthrough at CERN

Science Daily: Pharmacology News

Deep beneath the Swiss-French border, the Large Hadron Collider unleashes staggering amounts of energy and radiation—enough to fry most electronics. Enter a team of Columbia engineers, who built ultra-rugged, radiation-resistant chips that now play a pivotal role in capturing data from subatomic particle collisions. These custom-designed ADCs not only survive the hostile environment inside CERN but also help filter and digitize the most critical collision events, enabling physicists to study elu

article thumbnail

Chiglitazar

New Drug Approvals

Chiglitazar CAS 743438-45-1 Ingredient UNII CAS InChI Key Chiglitazar sodium, (S)- YN12H6OCV6 2390374-10-2 RMVIEXHXRDCWBT-UCRKPPETSA-M CS 038 Carfloglitazar, (s)- E6EJV1J6Y0 (2 S )-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid C 36 H 29 FN 2 O 4 572.6 g/mol (2S)-3-[4-(2-carbazol-9-ylethoxy)phenyl]-2-[2-(4-fluorobenzoyl)anilino]propanoic acid (2S)-3-(4-(2-CARBAZOL-9-YLETHOXY)PHENYL)-2-(2-(4-FLUOROBENZOYL)ANILINO)PROPANOIC ACID (2s)-3-(4-(2-carbazol-9-ylethoxy)ph